ES2641751T3 - Compuestos y métodos para reducir el reclutamiento y/o la migración de células polimorfonucleares - Google Patents

Compuestos y métodos para reducir el reclutamiento y/o la migración de células polimorfonucleares Download PDF

Info

Publication number
ES2641751T3
ES2641751T3 ES14154643.2T ES14154643T ES2641751T3 ES 2641751 T3 ES2641751 T3 ES 2641751T3 ES 14154643 T ES14154643 T ES 14154643T ES 2641751 T3 ES2641751 T3 ES 2641751T3
Authority
ES
Spain
Prior art keywords
cells
administered
use according
pmn
pharmaceutical preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14154643.2T
Other languages
English (en)
Spanish (es)
Inventor
Charlotte Admyre
Lars-Göran AXELSSON
Oliver Von Stein
Arezou Zargari
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Index Pharmaceuticals AB
Original Assignee
Index Pharmaceuticals AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Index Pharmaceuticals AB filed Critical Index Pharmaceuticals AB
Application granted granted Critical
Publication of ES2641751T3 publication Critical patent/ES2641751T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
ES14154643.2T 2008-11-04 2009-10-28 Compuestos y métodos para reducir el reclutamiento y/o la migración de células polimorfonucleares Active ES2641751T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11128408P 2008-11-04 2008-11-04
US111284P 2008-11-04
SE0802338 2008-11-04
SE0802338 2008-11-04

Publications (1)

Publication Number Publication Date
ES2641751T3 true ES2641751T3 (es) 2017-11-13

Family

ID=42153087

Family Applications (2)

Application Number Title Priority Date Filing Date
ES14154643.2T Active ES2641751T3 (es) 2008-11-04 2009-10-28 Compuestos y métodos para reducir el reclutamiento y/o la migración de células polimorfonucleares
ES09825058.2T Active ES2464731T3 (es) 2008-11-04 2009-10-28 Compuestos y procedimientos para reducir el reclutamiento y/o migración de células polimorfonucleares

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES09825058.2T Active ES2464731T3 (es) 2008-11-04 2009-10-28 Compuestos y procedimientos para reducir el reclutamiento y/o migración de células polimorfonucleares

Country Status (11)

Country Link
US (2) US8877724B2 (enExample)
EP (2) EP2806028B1 (enExample)
JP (1) JP5749651B2 (enExample)
AU (1) AU2009311748B2 (enExample)
CA (1) CA2778938C (enExample)
DK (2) DK2342341T3 (enExample)
ES (2) ES2641751T3 (enExample)
HR (1) HRP20171360T1 (enExample)
LT (1) LT2806028T (enExample)
PL (1) PL2806028T3 (enExample)
WO (1) WO2010053430A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5746038B2 (ja) * 2008-11-04 2015-07-08 インデックス・ファーマシューティカルズ・アクチエボラーグ Ｃｎｓの炎症性疾患の治療のための化合物および方法
EP2468866A1 (en) 2010-12-21 2012-06-27 Index Pharmaceuticals AB Biologically active oligonucleotides capable of modulating the immune system
WO2012084991A1 (en) 2010-12-21 2012-06-28 Index Pharmaceuticals Ab Biologically active oligonucleotides capable of modulating the immune system ii
EP2468867A1 (en) 2010-12-21 2012-06-27 Index Pharmaceuticals AB Methods for identifying biologically active oligonucleotides capable of modulating the immune system
ES2870458T3 (es) 2010-12-21 2021-10-27 Index Pharmaceuticals Ab Oligonucleótidos biológicamente activos capaces de modular el sistema inmunitario
US9873878B2 (en) * 2015-03-30 2018-01-23 University Of Louisville Research Foundation, Inc. Compositions and methods for use in treating silicosis and lung cancer
AU2017368050A1 (en) 2016-11-29 2019-06-20 Puretech Lyt, Inc. Exosomes for delivery of therapeutic agents
JP2021131228A (ja) * 2018-04-27 2021-09-09 国立大学法人 東京大学 難治性喘息の予防又は治療剤をスクリーニングする方法、及び難治性喘息の予防又は治療剤

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6172208B1 (en) * 1992-07-06 2001-01-09 Genzyme Corporation Oligonucleotides modified with conjugate groups
SE9602300D0 (sv) * 1996-06-11 1996-06-11 Karolinska Innovations Ab New composition and methods
CA2365204C (en) 1999-03-18 2009-10-27 Brigham And Women's Hospital Lipoxin compounds and their use
US6489311B1 (en) * 2000-05-02 2002-12-03 Charlotte-Mecklenburg Hospital Authoirty Method for the prevention of apoptosis
WO2004110477A1 (en) * 2003-06-19 2004-12-23 Ctt Cancer Targeting Technologies Oy Inhibitors of the leukocyte prommp-9/beta(2) integrin complex
SE0400399D0 (sv) 2004-02-20 2004-02-20 Index Pharmaceuticals Ab Methods and compositions for the treatment or prevention of secondary ischemic injury
WO2007030581A2 (en) * 2005-09-09 2007-03-15 Oregon Health & Science University Neuroprotectants
WO2007030580A2 (en) * 2005-09-09 2007-03-15 Oregon Health & Science University Neuroprotectants
JP5346923B2 (ja) 2007-05-04 2013-11-20 インデックス・ファーマシューティカルズ・アクチエボラーグ 腫瘍増殖阻害化合物及びそれらの使用方法
US20110280934A1 (en) 2008-11-04 2011-11-17 Asa Karlsson Increased Expression of Specific Antigens
JP5746038B2 (ja) 2008-11-04 2015-07-08 インデックス・ファーマシューティカルズ・アクチエボラーグ Ｃｎｓの炎症性疾患の治療のための化合物および方法

Also Published As

Publication number Publication date
US20110301225A1 (en) 2011-12-08
AU2009311748A1 (en) 2010-05-14
AU2009311748B2 (en) 2014-08-21
LT2806028T (lt) 2017-12-11
EP2806028A2 (en) 2014-11-26
US20150099799A1 (en) 2015-04-09
HRP20171360T1 (hr) 2017-11-03
DK2342341T3 (da) 2014-05-12
JP5749651B2 (ja) 2015-07-15
EP2342341B1 (en) 2014-03-05
JP2012507307A (ja) 2012-03-29
US8877724B2 (en) 2014-11-04
CA2778938A1 (en) 2010-05-14
EP2806028A3 (en) 2015-03-11
EP2342341A4 (en) 2013-01-09
DK2806028T3 (en) 2017-10-09
WO2010053430A1 (en) 2010-05-14
ES2464731T3 (es) 2014-06-03
EP2342341A1 (en) 2011-07-13
PL2806028T3 (pl) 2017-11-30
US10046006B2 (en) 2018-08-14
EP2806028B1 (en) 2017-07-12
CA2778938C (en) 2019-07-02

Similar Documents

Publication Publication Date Title
ES2464731T3 (es) Compuestos y procedimientos para reducir el reclutamiento y/o migración de células polimorfonucleares
JP6707549B2 (ja) 抗老化化合物及びその使用
Baek et al. Extracellular taurine induces angiogenesis by activating ERK-, Akt-, and FAK-dependent signal pathways
JP5914567B2 (ja) 浮腫を治療または軽減するための新規な化合物およびその使用方法
CN109937053B (zh) 用于治疗黄斑变性的含有mTOR抑制剂的药物组合物
CN108670969B (zh) 一种治疗骨髓造血功能障碍的药物
ES2560782T3 (es) Compuestos y métodos para el tratamiento de enfermedades inflamatorias del SNC
CN111562394A (zh) 热休克因子2结合蛋白在肝脏缺血再灌注损伤、药物性肝损伤中的应用
CN108410878B (zh) 一种lrpprc特异性核酸适配体及其应用
US20240207211A1 (en) Composition for promoting bone formation or treating bone disease by acting on osteoblast mitochondria
ES2895154T3 (es) Engrailed para su uso en el tratamiento de daños en el ADN en un paciente que padece la enfermedad de Parkinson
JP5597534B2 (ja) 抗腫瘍性の薬物、医薬、組成物、およびその使用
ES2920052T3 (es) Formulaciones de alicaforsen
US7906621B2 (en) Anti-tumor drug, medicament, composition, and use thereof
ES2329039T3 (es) Utilizacion de etazol para el tratamiento de patologias neurodegenerativas oculares.
CA2999209C (en) Homeoproteins for use in the treatment of neurodegenerative disorders
AU2015347148B2 (en) Novel compositions for the treatment of cancer
KR101693186B1 (ko) ＰＡＮ-ＥｒｂＢ 억제제의 암 치료 효과 예측에 관한 정보 제공 방법
CA2616534A1 (en) Antitumor agent comprising 6'-amidino-2'-naphthyl4- guanidinobenzoate or salt thereof
US8372810B2 (en) Anti-tumor drug, medicament, composition, and use thereof
CN115245506A (zh) 大麻二酚在治疗三阴型乳腺癌药物研制中的应用
WO2021125932A1 (es) Composición farmacéutica para el tratamiento de enfermedades que cursan con fibrosis
CN113930423A (zh) 保护心肌细胞免受应激损伤的saRNA及其应用
Venosa Identification of distinct macrophage subpopulations during nitrogen mustard-induced lung injury and fibrosis: Mechanisms of recruitment and activation